Fast Five Quiz: Precision Medicine and Genetic Testing for Colorectal Cancer

Ali Alqahtani, MD


June 17, 2022

In the setting of ERBB2-amplified metastatic CRC, a favorable response to anti-HER2 therapies has been demonstrated. Trastuzumab deruxtecan, an antibody-drug conjugate, has shown promise in this setting. Currently, there are no approved HER2-targeted therapies for CRC.

Learn more about HER2-targeted therapies for metastatic CRC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.